Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Mingzhu Zhou, MSc"'
Autor:
Caicun Zhou, MD, PhD, You Lu, MD, Sang-We Kim, MD, PhD, Thanyanan Reungwetwattana, MD, Jianying Zhou, MD, Yiping Zhang, MD, Jianxing He, MD, PhD, Jin-Ji Yang, MD, Ying Cheng, MD, Se-Hoon Lee, MD, PhD, Jianhua Chang, MD, Jian Fang, MD, Zhe Liu, PhD, Lilian Bu, MSc, Li Qian, MD, Tingting Xu, MD, Venice Archer, MB ChB, MSc, Magalie Hilton, MSc, Mingzhu Zhou, MSc, Li Zhang, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100700- (2024)
Introduction: Previous results from the phase 3 ALESIA study (NCT02838420) revealed that alectinib (a central nervous system [CNS]-active, ALK inhibitor) had clinical benefits in treatment-naïve Asian patients with advanced ALK-positive NSCLC, consi
Externí odkaz:
https://doaj.org/article/0adb5b401a534eba8c323105cdaa5a38
